Background: Guidelines do not recommend that cancer outpatients receive thromboprophylaxis unless at high venous thromboembolism (VTE) risk, with the Khorana score suggested for risk stratification. This study investigated VTE incidence in outpatients with pancreatic, endometrial, colorectal, ovarian and cervical cancer, the role of Khorana score in risk assessment and potential risk factors.
Introduction
Venous thromboembolism (VTE) causes significant morbidity and mortality in patients with malignancy. The MEGA study (2005) demonstrated that the risk of VTE increased sevenfold in patients with cancer, and that the highest risk was immediately after diagnosis, in patients with metastatic disease, and in those with hematological malignancy [1] . Cancer VTE is the second leading cause of death in cancer patients, and it is a recognized independent risk factor for mortality [2] . Patients with cancer-associated thrombosis have an increased risk of VTE recurrence and major bleeding [3, 4] .
Risk assessment for VTE is now routine for both medical and surgical inpatients in the UK. International guidelines recommend thromboprophylaxis in surgical inpatients with a moderate VTE risk of 3%, provided bleeding risk is not high, and also in medical inpatients at a high risk (11%) of VTE [5, 6] . However, the role of thromboprophylaxis in outpatients with cancer is less clear, with guidance recommending that prophylaxis is not used routinely, but considered for those at high thrombotic risk [5, 7] . Some guidelines suggest risk stratification using the Khorana score (Table 1) with thromboprophylaxis considered in patients with a high risk score (≥ 3) [8, 9] .
We undertook a retrospective cohort study to investigate VTE incidence in the first year of diagnosis in outpatients diagnosed with pancreatic, endometrial, colorectal, ovarian or cervical cancer, at a large tertiary cancer center. We reviewed the association with Khorana score at cancer diagnosis and investigated the role of other risk factors in development of cancer VTE. Stepwise logistic regression using backward elimination was then performed for each cancer type, using a significance level for removal from the model of α = 0.05. This tested which of the VTE risk factors remained statistically significant after adjusting for the other factors. All analysis was completed using Stata version 14.0 (StataCorp, College Station, TX, USA, 2015).
VTE in Ambulatory Cancer

Results
There were 878 new diagnoses of pancreatic, endometrial, colorectal, ovarian and cervical cancer between December 1, 2012 (or December 1, 2009 for pancreatic) and December 31, 2014 ( Fig. 1 , STROBE diagram). One hundred thirteen patients were excluded from the study because of pre-existing anticoagulation or incomplete data. Nineteen further patients were excluded as the thrombotic event occurred during patient admission or within 90 days of discharge or surgery (hospital acquired thrombosis (HAT)). Seven hundred forty-six patients were therefore included in the study: 97 pancreatic cancer diagnoses, 157 endometrial cancer, 205 colorectal cancer, 196 ovarian cancer and 91 cervical cases. Patients who presented with a VTE at time of cancer diagnosis (n = 16) were excluded from the subsequent VTE risk factor analysis. Patient and treatment characteristics of patients included in the VTE risk factor analysis are shown in Table 2 .
VTE incidence
Rates of total VTEs and potentially preventable VTEs (Fig. 2) were recorded for each cancer group.
VTE demographics
Pancreatic cancer
Twenty-six patients with VTE diagnosed during the first year of cancer diagnosis developed 31 individual clots (nine lower limb deep vein thrombosis (LL-DVT), three upper limb DVT (UL-DVT) (all central venous catheter (CVC)-associated), five pulmonary emboli (PE), one inferior vena cava (IVC) and 13 intra-abdominal thromboses comprising of portal, splenic, hepatic, superior mesenteric and renal vein thromboses). Of these patients, 13/26 had symptomatic VTE, while the remaining patients had VTE incidentally found on staging scans; the majority of these were intra-abdominal VTE (five portal vein, four splenic vein, one hepatic vein, one renal vein and one superior mesenteric vein) as well as two incidental PEs. Of the patients, 14/26 were treated with low molecular weight heparin (LWMH). Untreated patients were asymptomatic or had contraindication to anticoagulation.
Endometrial cancer
Nine patients with VTE diagnosed during the first year of diagnosis developed 10 individual clots (two LL-DVT, one UL-DVT (CVC-associated) and seven PE). Six out of nine were symptomatic, with three incidental PEs found on staging CT scans. All received treatment dose LMWH.
Colorectal cancer
Twenty patients with VTE diagnosed within the first year developed 21 individual VTE episodes (five LL-DVT, five UL-DVT (all CVC-associated), eight PE, one neck and two portal vein thromboses). Nine out of 20 patients were asymptomatic (seven incidentally found PE and two incidentally found portal vein thromboses on staging scans). The majority of patients (18/20) were treated with LMWH. Of the remaining two patients, one died prior to treatment commencing, and the other had a small non-occlusive CVC-associated DVT which was managed by removal of the line only.
Ovarian cancer
Twenty patients with VTE diagnosed within the first year developed 23 individual clots (five lower limb DVT, four upper limb DVT (all peripherally inserted central catheter (PICC)-associated), 12 pulmonary emboli and two inferior vena cava thromboses). Fourteen out of 21 patients had symptomatic VTE, seven asymptomatic, one patient had three individual events (one symptomatic PE, followed by separate lower limb and IVC thromboses incidentally found on staging scans). Twenty out of 21 patients received LMWH. In the remaining patient, anticoagulation was contraindicated because of high bleeding risk outweighing benefit for treating small incidental PEs.
Cervical cancer
None of the 91 patients diagnosed with cervical cancer had a VTE unrelated to an inpatient stay or surgery in the first year following diagnosis.
Association with Khorana score
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Austin et al J Hematol. 2019;8(1):17-25 groups by Khorana score at diagnosis (excluding those with abdominal VTE). In all groups except for endometrial cancer, a high risk Khorana score was not associated with a higher VTE rate (Fig. 3a-d) .
Association with other variables
The association between the development of VTE in the first year of cancer diagnosis with background and treatment variables were analyzed (Table 3) . In all cancer groups (excluding cervical cancer where no patient developed a VTE), VTE development was univariately associated with indwelling CVCs (P < 0.05). In endometrial and colorectal cancers, chemotherapy use was significantly associated with VTE development, and in pancreatic, endometrial and ovarian cancers, surgical intervention was significantly associated, even after exclusion of VTE occurring within 90 days of surgery. BMI was only associated with VTE development in ovarian cancer, and full blood count parameters used in the calculation of the Khorana score (platelet count ≥ 350 × 10 9 , Hb level < 100 g/L and leukocyte count > 11 × 10 9 ) were only associated with VTE development in endometrial cancer. Finally, advanced stage of cancer was univariately associated with VTE development in endometrial and ovarian cancer. Risk factors that remained statistically significant after stepwise logistic regression were indwelling CVC for endometrial, colorectal and ovarian cancers; chemotherapy for pancreatic cancer only; surgery for endometrial and ovarian cancers; Hb < 100 g/L for pancreatic cancer; BMI > 35 for ovarian cancer; and surgical intervention for endometrial and ovarian cancers.
The VTE rate for patients with indwelling lines were: 34.8% (8/23) for pancreatic; 25.0% (2/8) for endometrial; 22.6% (14/62) for colorectal and 22.7% (5/22) for ovarian. The VTE rate for patients having chemotherapy were: 23.2% (13/56) for pancreatic; 9.1% (4/44) for endometrial; 16.4% (19/116) for colorectal and 10.1% (15/148) for ovarian. Numbers were too small for further subgroup partitioning within subgroups.
The number of days between cancer and potentially preventable VTE diagnosis was calculated. The median (IQR) time to VTE was 24 days in endometrial cancer (7 - 
Discussion
This retrospective cohort study of ambulatory cancer patients demonstrates a significant burden of VTE in the first year of diagnosis in four out of five cancer groups analyzed. The exception to this is cervical cancer in which there were no VTE unrelated to an inpatient stay or surgery. However, four out of 91 cervical cancer patients developed VTE which were all associated with short day-case surgical procedures (three EUA and one laparoscopic EUA) defined as "low risk" on local VTE risk assessment and thus did not receive postoperative thromboprophylaxis
The total rates of VTE were 26.8%, 5.7%, 9.8%, 10.2% and 0.0% for pancreatic, endometrial, colorectal, ovarian and cervical cancers, respectively. Even excluding those patients who presented with VTE or had thrombosis diagnosed on initial staging scans, the majority of patients with these cancers had a VTE that was potentially preventable with thromboprophylaxis. However, this is not routine clinical practice for outpatients, despite being a quality standard in hospitalized patients [10] . International ACCP guidelines currently recommend that clinicians should not routinely offer pharmacological VTE prophylaxis to outpatients with cancer, but recommend prophylactic LMWH for patients with low bleeding risk and additional risk factors including previous VTE, immobilization, hormonal therapies, angiogenesis inhibitors, thalidomide and lenalidomide [5] . More recent guidelines suggest the use of the Khorana score for risk stratification [8] . However, our data suggest that the Khorana score is not valuable in risk stratifying patients with pancreatic, colorectal and ovarian cancers, although a higher Khorana score was predictive of 1-year VTE development in endometrial cancer. Furthermore, use of the Khorana score to define who may benefit from prophylactic anticoagulation in the cervical cancer cohort would have potentially meant all 25 patients with a high-risk score were unnecessarily anticoagulated, since none developed a VTE which was not associated with an inpatient admission or surgery.
We investigated other variables associated with VTE development in ambulatory cancer patients. Risk factors which remained statistically significant after stepwise logistic regression were indwelling CVC for endometrial, colorectal and ovarian cancers; chemotherapy for pancreatic cancer only; surgery for endometrial and ovarian cancers; Hb < 100 g/L for pancreatic cancer and BMI > 35 for ovarian cancer. The VTE rate for patients with indwelling lines was particularly high, with around a quarter of endometrial, colorectal and ovarian; and over a third of pancreatic cancer patients with CVC developing VTE, either local or systemic.
Improving risk stratification in ambulatory cancer patients is likely to have an impact on morbidity due to the high burden of VTE incidence demonstrated in this study. The VTE risk in patients with malignancy is greatest in the first year follow- ing diagnosis, so it is important to develop simple and reliable methods to risk stratify in the MDT or outpatient department soon after diagnosis [11] . Despite some studies suggesting that bleeding rates with use of anticoagulants in cancer patients are higher than in patients without malignancy, large studies have refuted this and there is no evidence suggesting this is the case with primary thromboprophylaxis [7, 12] . An obvious limitation is that this is a retrospective study. However, it includes a large cohort and provides important information to guide future prospective investigations of thromboprophylaxis in ambulatory cancer patients, in particular, factors to identify those at high risk. Oncology care was delivered at our tertiary center but some patients may have consulted their local hospitals with acute presentations, including of VTE. Thus, our data may in fact underestimate the incidence of VTEs and this may explain in part why there were no VTE diagnoses in the cervical cancer cohort. Future multicenter prospective studies looking at additional tumor groups would be of value in further evaluating the extent of the clinical problem.
In summary, this retrospective cohort study at a tertiary oncology center has identified a significant burden of VTE in pancreatic, endometrial, colorectal and ovarian cancer cohorts. Khorana score did not predict risk of VTE development in pancreatic, colorectal, ovarian or cervical cancer groups, although it was predictive in patients with endometrial cancer. The major variable associated with VTE development was indwelling CVC with VTE rates of 23-35% depending on tumor type. Our data suggest a role for clinical trials of routine thromboprophylaxis in targeted groups of cancer outpatients, such as those with pancreatic cancer, or with endometrial, colorectal and ovarian cancers and indwelling CVCs.
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